Atrial fibrillation (AF) is the most commonly diagnosed cardiac arrhythmia and is associated with increased morbidity and mortality. Currently approved AF antiarrhythmic drugs have limited efficacy and/or carry the risk of ventricular pro-arrhythmia. The cardiac acetylcholine activated inwardly rectifying K current (I), composed of Kir3.1/Kir3.4 heterotetrameric and Kir3.4 homotetrameric channel subunits, is one of the best validated atrial-specific ion channels. Previous research pointed to a series of benzopyran derivatives with potential for treatment of arrhythmias, but their mechanism of action was not defined. Here, we characterize one of these compounds termed Benzopyran-G1 (BP-G1), and report that it selectively inhibits the Kir3.1 (GIRK1 or G1) subunit of the K channel. Homology modeling, molecular docking, and Molecular Dynamics simulations predicted that BP-G1 inhibits the I channel by blocking the central cavity pore. We identified the unique F137 residue of Kir3.1 as the critical determinant for the I-selective response to BP-G1. The compound interacts with Kir3.1 residues E141 and D173 through hydrogen bonds that proved critical for its inhibitory activity. BP-G1 effectively blocked the I channel response to carbachol in an in vivo rodent model, and displayed good selectivity and pharmacokinetic properties. Thus, BP-G1 is a potent and selective small molecule inhibitor targeting Kir3.1-containing channels and is a useful tool for investigating the role of Kir3.1 heteromeric channels in vivo. The mechanism reported here could provide the molecular basis for future discovery of novel, selective I channel blockers to treat atrial fibrillation with minimal side effects.
Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.

Author